Twist Bioscience Corporation TWST NASDAQ

Twist Bioscience Corporation (TWST) generated $-47.63M in operating cash flow for fiscal year 2025. After capital expenditures of $28M, free cash flow was $-75.63M.

Free cash flow margin was -20.1% of revenue. Cash conversion ratio was 0.61x, suggesting some earnings are non-cash.

The company returned $16K in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (70/100, Pass) — $-75.63M (-20.1% FCF margin) supports a durable competitive advantage
• INCOME (10/100) — Cash conversion ratio was 0.61x suggests some earnings are non-cash items

Overall SharesGrow Score: 55/100 with 3/7 criteria passed.